Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody, which is in Phase 2b clinical trial for the treatment of atopic dermatitis; ISB 1302, a HER2 X CD3 beat bispecific antibody that is in Phase 1/2 clinical trial for the treatment of metastatic HER2-positive breast cancer; and ISB 1342, a CD38 X CD3 beat bispecific antibody, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma. The company's pre-clinical stage product pipeline comprises ISB 880 for the treatment of anti-inflammatory therapy; ISB 1908 and ISB 1909 T-cell engagers for the treatment of oncology; ISB 1442, an innate immune engager for the treatment of oncology; and GRC 39815, an inhibitor of the retinoid-related orphan receptor gamma for the treatment of chronic obstructive pulmonary disorder. It also offers Ryaltris nasal spray for allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals focuses on the development and manufacturing of high-quality branded and generic medicines for global markets. The company is engaged in creating centers of excellence in dermatology, oncology, and respiratory therapy.

Metric
Company Name	Glenmark Pharmaceuticals Limited
Symbol	GLENMARK
MSH ID	COM:GLENMARKPHARMA
Market	STOCKS
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
Country	IN
Stage
Employee Count	15.56K
Website	glenmarkpharma.com
LinkedIn
Founders

Metric
Market Cap	4.61B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	1.39B
Revenue (LTM)
Revenue (NTM)
Gross Profit	466.30M
EBITDA	141.12M
Operating Income	72.42M
Net Income	-177.29M
EPS	-0.63
Diluted EPS	-0.63
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.62
Operating Profit Margin	0.07
EBITDA Margin	0.10
Net Profit Margin	-0.06
Return on Equity	-0.07
Return on Assets
Return on Capital Employed	0.10

NSE:GLENMARK

Glenmark Pharmaceuticals

Last Close

1,478.20

25/11 09:40

Market Cap

390.66B

Beta: 0.73

Volume Today

654.54K

Avg: 1.36M

PE Ratio

−284.91

PFCF: 3,684.76

Dividend Yield

0.28%

Payout:0%

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-284.91
P/B Ratio	2.68
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	4.30
EV Multiple	36.82

Metric
Days Sales Outstanding	161.17
Days Payables Outstanding	146.28
Days Inventory Outstanding	172.88
Operating Cycle	229.31
Cash Conversion Cycle	55.48
Asset Turnover	0.84

Metric
Operating Cash Flow	-90.32M
Free Cash Flow	-198.34M
Cash Flow to Debt	0.83
Operating Cash Flow/Sales	0.07
Free Cash Flow Yield	0.00

Metric
Cash & Equivalents	195.92M
Accounts Receivable	114.46M
Inventory	296.69M
Goodwill	7.95M
Debt to Capitalization	0.14
Debt to Assets	0.26
Current Ratio	1.93
Quick Ratio	0.84

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.00
R&D to Revenue
SG&A to Revenue